All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This octapeptide is amino acids 52 to 59 fragment of the the vesicular stomatitis virus (VSV) nucleoprotein. VSV-8 is derived from the VSV nucleoprotein that is expressed in the cytosol of the infected cells. CTL response against VSV in H-2Kb mice is directed against this single VSV-8 immunodominant peptide. This peptide forms complex with murine MHC class I molecule H-2Kb, which is similar to human HLA class I.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-L121 | Human anti-VSV8 (RGYVYQGL) T Cell Receptor, pMSGV1 | VSIV | Human | RGYVYQGL | retroviral vector | |||
TCR-L120Z | Human anti-vesicular stomatitis virus octapeptide (VSV8) (aa 52-59) T cell receptor, pCDTCR1 | VSIV | Human | RGYVYQGL | Lentiviral | |||
TCR-C257Z | Mouse anti-VSV8 T cell receptor (BM3.3), pCDTCR1 | VSIV | BM3.3 | Mouse | RGYVYQGL | H-2Kb | Lentiviral | |
TCR-C258Z | Mouse anti-VSV8 T cell receptor (N15), pCDTCR1 | VSIV | N15 | Mouse | RGYVYQGL | H-2Kb | Lentiviral |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION